US Patent

US12403095 — Stabilized tacrolimus composition

Formulation · Assigned to Veloxis Pharmaceuticals Inc · Expires 2028-05-30 · 2y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stable pharmaceutical composition of tacrolimus, specifically a solid dispersion with a stabilizing agent that prevents degradation.

USPTO Abstract

The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising e stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.

Drugs covered by this patent

Patent Metadata

Patent number
US12403095
Jurisdiction
US
Classification
Formulation
Expires
2028-05-30
Drug substance claim
No
Drug product claim
Yes
Assignee
Veloxis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.